About Proteon Therapeutics (NASDAQ:PRTO)
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRTO
CUSIPN/A
Phone781-890-0102
Debt
Debt-to-Equity RatioN/A
Current Ratio4.71%
Quick Ratio4.71%
Price-To-Earnings
Trailing P/E Ratio-1.06
Forward P/E Ratio-1.56
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.75 per share
Price / Book3.00
Profitability
EPS (Most Recent Fiscal Year)($2.13)
Net Income$-29,960,000.00
Net MarginsN/A
Return on Equity-128.00%
Return on Assets-73.90%
Miscellaneous
Employees16
Outstanding Shares17,670,000
Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions
What is Proteon Therapeutics' stock symbol?
Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."
How were Proteon Therapeutics' earnings last quarter?
Proteon Therapeutics (NASDAQ:PRTO) released its quarterly earnings data on Wednesday, March, 14th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.14. View Proteon Therapeutics' Earnings History.
When is Proteon Therapeutics' next earnings date?
What price target have analysts set for PRTO?
5 Wall Street analysts have issued 12 month price objectives for Proteon Therapeutics' shares. Their forecasts range from $2.00 to $6.00. On average, they expect Proteon Therapeutics' share price to reach $3.6667 in the next year. View Analyst Ratings for Proteon Therapeutics.
Who are some of Proteon Therapeutics' key competitors?
Some companies that are related to Proteon Therapeutics include Cidara Therapeutics (CDTX), aTyr Pharma (LIFE), Genocea Biosciences (GNCA), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Vaxart (VXRT), Vical (VICL), Microbot Medical (MBOT), Neuralstem (CUR), Oncobiologics (ONS), TrovaGene (TROV), Windtree Therapeutics (WINT) and OXiGENE (MATN).
Who are Proteon Therapeutics' key executives?
Proteon Therapeutics' management team includes the folowing people:
- Mr. Timothy P. Noyes, CEO, Pres & Director (Age 56)
- Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 55)
- Dr. Steven Keith Burke M.D., Sr. VP & Chief Medical Officer (Age 57)
- Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 45)
- Mr. Daniel P. Gottlieb, VP of Corp. Devel. (Age 48)
Has Proteon Therapeutics been receiving favorable news coverage?
Media stories about PRTO stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteon Therapeutics earned a news impact score of 0.09 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 44.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Proteon Therapeutics?
Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteon Therapeutics' stock price today?
One share of PRTO stock can currently be purchased for approximately $2.25.
How big of a company is Proteon Therapeutics?
Proteon Therapeutics has a market capitalization of $41.54 million. The biopharmaceutical company earns $-29,960,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Proteon Therapeutics employs 16 workers across the globe.
How can I contact Proteon Therapeutics?
Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]
MarketBeat Community Rating for Proteon Therapeutics (PRTO)
MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe PRTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Proteon Therapeutics (NASDAQ:PRTO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Proteon Therapeutics in the last 12 months. Their average twelve-month price target is $3.6667, suggesting that the stock has a possible upside of 62.96%. The high price target for PRTO is $6.00 and the low price target for PRTO is $2.00. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.40 | 2.40 | 2.20 | 2.11 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.6667 | $3.6667 | $3.4333 | $9.00 |
| Price Target Upside: | 62.96% upside | 70.54% upside | 85.59% upside | 592.31% upside |
Proteon Therapeutics (NASDAQ:PRTO) Consensus Price Target History
Proteon Therapeutics (NASDAQ:PRTO) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Proteon Therapeutics (NASDAQ:PRTO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Proteon Therapeutics (NASDAQ PRTO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 36.30%
Institutional Ownership Percentage: 50.39%
Proteon Therapeutics (NASDAQ PRTO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/15/2017 | Steven Keith Burke | SVP | Buy | 12,000 | $1.88 | $22,560.00 | 117,535 |  |
| 11/30/2017 | James E Flynn | Director | Buy | 110,557 | $1.75 | $193,474.75 | | |
| 11/14/2017 | George Arthur Eldridge | CFO | Buy | 295 | $1.69 | $498.55 | | |
| 6/6/2016 | George Arthur Eldridge | CFO | Buy | 4,000 | $5.78 | $23,120.00 | 2,750 | |
| 12/1/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $14.97 | $74,850.00 | | |
| 11/2/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.50 | $67,500.00 | | |
| 10/1/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.33 | $66,650.00 | | |
| 9/8/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.55 | $67,750.00 | | |
| 7/7/2015 | Daniel Philip Gottlieb | VP | Sell | 1,965 | $16.86 | $33,129.90 | | |
| 10/27/2014 | James E Flynn | Insider | Buy | 691,713 | $10.00 | $6,917,130.00 | | |
| 10/27/2014 | Skyline Venture Partners Quali | Major Shareholder | Sell | 56,038 | $10.00 | $560,380.00 | | |
| 10/27/2014 | Timothy Haines | Director | Buy | 950,000 | $10.00 | $9,500,000.00 | | |
(Data available from 1/1/2013 forward)
Proteon Therapeutics (NASDAQ PRTO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Proteon Therapeutics (PRTO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 18 at 7:24 PM |
| Proteon Therapeutics (PRTO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 18 at 5:18 PM |
| Proteon Therapeutics (PRTO) Given a $2.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 11 at 11:52 PM |
| Analysts Anticipate Proteon Therapeutics (PRTO) to Post -$0.35 Earnings Per Share
www.americanbankingnews.com - April 10 at 11:16 PM |
| Proteon Therapeutics (PRTO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:03 AM |
| Proteon Therapeutics (PRTO) Given Hold Rating at HC Wainwright
www.americanbankingnews.com - April 1 at 10:29 AM |
| Proteon Therapeutics (PRTO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 28 at 9:48 PM |
| Zacks: Analysts Anticipate Proteon Therapeutics Inc (PRTO) to Post -$0.35 Earnings Per Share
www.americanbankingnews.com - March 25 at 1:26 AM |
| Proteon Therapeutics Inc (PRTO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 7:33 PM |
| Proteon Therapeutics (PRTO) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 18 at 11:14 AM |
| Proteon Therapeutics (PRTO) Given a $3.00 Price Target by Robert W. Baird Analysts
www.americanbankingnews.com - March 17 at 2:18 PM |
| Proteon Therapeutics (PRTO) PT Set at $2.00 by HC Wainwright
www.americanbankingnews.com - March 16 at 7:47 PM |
| Robert W. Baird Reaffirms Outperform Rating for Proteon Therapeutics (PRTO)
www.americanbankingnews.com - March 16 at 7:12 PM |
| Proteon Therapeutics (PRTO) Posts Earnings Results, Beats Estimates By $0.14 EPS
www.americanbankingnews.com - March 15 at 1:56 PM |
 | Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?
finance.yahoo.com - March 14 at 10:10 AM |
| Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 14 at 10:10 AM |
| Analysts Anticipate Proteon Therapeutics Inc (PRTO) to Post -$0.43 EPS
www.americanbankingnews.com - March 7 at 5:11 PM |
| Proteon Therapeutics (PRTO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM |
| Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
finance.yahoo.com - March 5 at 5:10 PM |
| Analyzing Proteon Therapeutics (PRTO) & Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - February 6 at 1:14 AM |
| Proteon Therapeutics Inc (PRTO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 7:42 PM |
| Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - February 2 at 1:16 AM |
| Proteon Therapeutics (PRTO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 7 at 11:52 PM |
| Zacks: Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - December 30 at 7:46 AM |
| Reviewing Aduro BioTech (ADRO) and Proteon Therapeutics (PRTO)
www.americanbankingnews.com - December 25 at 11:42 PM |
| Proteon Therapeutics Inc (PRTO) SVP Steven Keith Burke Purchases 12,000 Shares
www.americanbankingnews.com - December 18 at 6:52 PM |
| Proteon Therapeutics Inc (PRTO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 14 at 9:28 PM |
| Reviewing Proteon Therapeutics (PRTO) and The Competition
www.americanbankingnews.com - December 14 at 1:28 PM |
| -$0.43 EPS Expected for Proteon Therapeutics Inc (PRTO) This Quarter
www.americanbankingnews.com - December 13 at 3:24 AM |
| Proteon Therapeutics (PRTO) & Its Peers Financial Contrast
www.americanbankingnews.com - December 9 at 3:14 AM |
| Proteon Therapeutics (PRTO) and Its Peers Head-To-Head Review
www.americanbankingnews.com - December 9 at 3:14 AM |
| Proteon Therapeutics Inc (PRTO) Director Acquires $193,474.75 in Stock
www.americanbankingnews.com - December 4 at 6:36 PM |
| Critical Contrast: Proteon Therapeutics (PRTO) versus Its Peers
www.americanbankingnews.com - December 4 at 1:30 PM |
| -$0.41 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
www.americanbankingnews.com - November 25 at 9:26 AM |
| Proteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 19 at 5:34 PM |
| Analyzing Proteon Therapeutics (PRTO) & The Competition
www.americanbankingnews.com - November 16 at 3:36 PM |
| Proteon Therapeutics, Inc. (PRTO) Earns "Hold" Rating from Robert W. Baird
www.americanbankingnews.com - November 11 at 11:12 AM |
| Proteon Therapeutics, Inc. (PRTO) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - November 11 at 7:16 AM |
| Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th
finance.yahoo.com - November 9 at 11:56 AM |
| Proteon Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 9:03 AM |
| Proteon Therapeutics reports 3Q loss
finance.yahoo.com - November 7 at 9:03 AM |
| -$0.40 EPS Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
www.americanbankingnews.com - November 6 at 9:59 AM |
| Critical Comparison: Biopharmx Corp (BPMX) vs. Proteon Therapeutics (PRTO)
www.americanbankingnews.com - November 4 at 9:28 PM |
| Critical Review: Intec Pharma (NTEC) vs. Proteon Therapeutics (PRTO)
www.americanbankingnews.com - November 1 at 2:20 PM |
| Proteon Therapeutics, Inc. (PRTO) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:54 AM |
| Proteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 25 at 9:52 PM |
| Zacks Investment Research Downgrades Proteon Therapeutics, Inc. (PRTO) to Hold
www.americanbankingnews.com - October 18 at 6:08 AM |
| Zacks: Brokerages Anticipate Proteon Therapeutics, Inc. (PRTO) to Post -$0.40 EPS
www.americanbankingnews.com - October 17 at 6:22 PM |
| Proteon Therapeutics, Inc. (PRTO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 30 at 8:34 PM |
| Head-To-Head Contrast: NeuroDerm (NDRM) & Proteon Therapeutics (PRTO)
www.americanbankingnews.com - September 22 at 6:06 AM |
Proteon Therapeutics (NASDAQ:PRTO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Proteon Therapeutics (NASDAQ:PRTO) Income Statement, Balance Sheet and Cash Flow Statement
Proteon Therapeutics (NASDAQ PRTO) Stock Chart for Saturday, April, 21, 2018
Loading chart…
